Cingulate to Host CNS Key Opinion Leader Panel in New York
Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations...
Source: globenewswire.com
📰 Nasdaq Cingw News
Nasdaq Cingw News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Cingw. Real-time updates on events, politics, business and more.
Cingulate Inc. Reports First Quarter 2023 Financial Results
Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for...
Source: globenewswire.com
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301,
Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in...
United States San Francisco Shanej Schaffer Adult Laboratory Setting Drug Administration Cingulate Inc
Source: globenewswire.com
Cingulate and ADHD Expert Dr. Ann Childress, MD to
KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary...
Source: globenewswire.com
Cingulate Inc. Announces Pricing of $25.0 Million Initial
KANSAS CITY, Kan., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing...
Source: globenewswire.com